Agilent Technologies, Inc. (NYSE: A) Stock Competitors & Peer Comparison
See A's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for A and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| A | $138.37 | -0.25% | 39.1B | 23.82 | $5.81 | +0.73% |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.73% |
| TMO | $574.30 | -0.43% | 213.4B | 24.79 | $23.16 | +0.31% |
| DHR | $194.98 | -0.61% | 137.1B | 24.45 | $7.98 | +0.73% |
| IDXX | $559.07 | +0.05% | 44.1B | 41.17 | $13.58 | N/A |
| IQV | $235.02 | -1.16% | 38.7B | 19.38 | $12.13 | N/A |
| NTRA | $267.76 | -0.70% | 38.3B | -168.40 | -$1.59 | N/A |
| ILMN | $205.10 | +0.00% | 31B | 40.78 | $5.03 | N/A |
| MTD | $1,416.30 | +2.59% | 28.6B | 32.58 | $43.51 | N/A |
| DGX | $233.01 | -0.55% | 25.7B | 22.98 | $10.14 | +1.41% |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
A vs DHR-PB Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, A's ROE is +0.21%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, A is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for A.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
A vs TMO Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, TMO has a market cap of 213.4B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while TMO trades at $574.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas TMO's P/E ratio is 24.79. In terms of profitability, A's ROE is +0.21%, compared to TMO's ROE of +0.13%. Regarding short-term risk, A is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for A.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
A vs DHR Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, DHR has a market cap of 137.1B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while DHR trades at $194.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas DHR's P/E ratio is 24.45. In terms of profitability, A's ROE is +0.21%, compared to DHR's ROE of +0.08%. Regarding short-term risk, A is less volatile compared to DHR. This indicates lower risk in terms of short-term price fluctuations for A.Check DHR's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
A vs IDXX Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, IDXX has a market cap of 44.1B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while IDXX trades at $559.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas IDXX's P/E ratio is 41.17. In terms of profitability, A's ROE is +0.21%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, A is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for A.Check IDXX's competition here
IQVIA Holdings Inc. (NYSE: IQV)
A vs IQV Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, IQV has a market cap of 38.7B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while IQV trades at $235.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas IQV's P/E ratio is 19.38. In terms of profitability, A's ROE is +0.21%, compared to IQV's ROE of +0.22%. Regarding short-term risk, A is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for A.Check IQV's competition here
Natera, Inc. (NASDAQ: NTRA)
A vs NTRA Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, NTRA has a market cap of 38.3B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while NTRA trades at $267.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas NTRA's P/E ratio is -168.40. In terms of profitability, A's ROE is +0.21%, compared to NTRA's ROE of -0.15%. Regarding short-term risk, A is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for A.Check NTRA's competition here
Illumina, Inc. (NASDAQ: ILMN)
A vs ILMN Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, ILMN has a market cap of 31B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while ILMN trades at $205.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas ILMN's P/E ratio is 40.78. In terms of profitability, A's ROE is +0.21%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, A is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for A.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
A vs MTD Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, MTD has a market cap of 28.6B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while MTD trades at $1,416.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas MTD's P/E ratio is 32.58. In terms of profitability, A's ROE is +0.21%, compared to MTD's ROE of -12.00%. Regarding short-term risk, A is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for A.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
A vs DGX Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, DGX has a market cap of 25.7B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while DGX trades at $233.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas DGX's P/E ratio is 22.98. In terms of profitability, A's ROE is +0.21%, compared to DGX's ROE of +0.14%. Regarding short-term risk, A is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for A.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
A vs LH Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, LH has a market cap of 25.4B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while LH trades at $309.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas LH's P/E ratio is 18.36. In terms of profitability, A's ROE is +0.21%, compared to LH's ROE of +0.12%. Regarding short-term risk, A is less volatile compared to LH. This indicates lower risk in terms of short-term price fluctuations for A.Check LH's competition here
Waters Corporation (NYSE: WAT)
A vs WAT Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, WAT has a market cap of 24.6B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while WAT trades at $377.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas WAT's P/E ratio is 27.78. In terms of profitability, A's ROE is +0.21%, compared to WAT's ROE of +0.08%. Regarding short-term risk, A is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for A.Check WAT's competition here
Guardant Health, Inc. (NASDAQ: GH)
A vs GH Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, GH has a market cap of 21.5B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while GH trades at $161.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas GH's P/E ratio is -62.79. In terms of profitability, A's ROE is +0.21%, compared to GH's ROE of +2.11%. Regarding short-term risk, A is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for A.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
A vs EXAS Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas EXAS's P/E ratio is -95.37. In terms of profitability, A's ROE is +0.21%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, A is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for A.Check EXAS's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
A vs ILMNV Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas ILMNV's P/E ratio is N/A. In terms of profitability, A's ROE is +0.21%, compared to ILMNV's ROE of N/A. Regarding short-term risk, A is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for A.Check ILMNV's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
A vs MEDP Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, MEDP has a market cap of 16.1B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while MEDP trades at $577.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas MEDP's P/E ratio is 36.27. In terms of profitability, A's ROE is +0.21%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, A is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for A.Check MEDP's competition here
PerkinElmer, Inc. (NYSE: PKI)
A vs PKI Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas PKI's P/E ratio is 41.45. In terms of profitability, A's ROE is +0.21%, compared to PKI's ROE of +0.03%. Regarding short-term risk, A is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for A.Check PKI's competition here
Revvity, Inc. (NYSE: RVTY)
A vs RVTY Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, RVTY has a market cap of 12.6B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while RVTY trades at $112.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas RVTY's P/E ratio is 21.98. In terms of profitability, A's ROE is +0.21%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, A is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for A.Check RVTY's competition here
ICON Public Limited Company (NASDAQ: ICLR)
A vs ICLR Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, ICLR has a market cap of 12.5B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while ICLR trades at $163.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas ICLR's P/E ratio is 13.34. In terms of profitability, A's ROE is +0.21%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, A is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for A.Check ICLR's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
A vs CRL Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, CRL has a market cap of 11.2B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while CRL trades at $232.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas CRL's P/E ratio is 23.25. In terms of profitability, A's ROE is +0.21%, compared to CRL's ROE of -0.06%. Regarding short-term risk, A is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for A.Check CRL's competition here
Qiagen N.V. (NYSE: QGEN)
A vs QGEN Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, QGEN has a market cap of 8.5B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while QGEN trades at $41.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas QGEN's P/E ratio is 17.25. In terms of profitability, A's ROE is +0.21%, compared to QGEN's ROE of +0.11%. Regarding short-term risk, A is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for A.Check QGEN's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
A vs BLLN Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, BLLN has a market cap of 6.4B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while BLLN trades at $138.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas BLLN's P/E ratio is 252.00. In terms of profitability, A's ROE is +0.21%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, A is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for A.Check BLLN's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
A vs TWST Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, TWST has a market cap of 5.7B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while TWST trades at $91.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas TWST's P/E ratio is -42.98. In terms of profitability, A's ROE is +0.21%, compared to TWST's ROE of -0.17%. Regarding short-term risk, A is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for A.Check TWST's competition here
Sotera Health Company (NASDAQ: SHC)
A vs SHC Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, SHC has a market cap of 5.1B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while SHC trades at $17.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas SHC's P/E ratio is 19.84. In terms of profitability, A's ROE is +0.21%, compared to SHC's ROE of +0.21%. Regarding short-term risk, A is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for A.Check SHC's competition here
RadNet, Inc. (NASDAQ: RDNT)
A vs RDNT Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, RDNT has a market cap of 5B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while RDNT trades at $63.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas RDNT's P/E ratio is 138.65. In terms of profitability, A's ROE is +0.21%, compared to RDNT's ROE of -0.01%. Regarding short-term risk, A is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for A.Check RDNT's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
A vs SYNH Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas SYNH's P/E ratio is 61.40. In terms of profitability, A's ROE is +0.21%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, A is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for A.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
A vs VCYT Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, VCYT has a market cap of 3.7B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while VCYT trades at $46.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas VCYT's P/E ratio is 23.16. In terms of profitability, A's ROE is +0.21%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, A is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for A.Check VCYT's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
A vs OLK Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas OLK's P/E ratio is -96.59. In terms of profitability, A's ROE is +0.21%, compared to OLK's ROE of -0.07%. Regarding short-term risk, A is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for A.Check OLK's competition here
Neogen Corporation (NASDAQ: NEOG)
A vs NEOG Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while NEOG trades at $12.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas NEOG's P/E ratio is 43.00. In terms of profitability, A's ROE is +0.21%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, A is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for A.Check NEOG's competition here
CareDx, Inc (NASDAQ: CDNA)
A vs CDNA Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, CDNA has a market cap of 2.3B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while CDNA trades at $43.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas CDNA's P/E ratio is 52.04. In terms of profitability, A's ROE is +0.21%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, A is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for A.Check CDNA's competition here
Personalis, Inc. (NASDAQ: PSNL)
A vs PSNL Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, PSNL has a market cap of 1.4B. Regarding current trading prices, A is priced at $138.37 on the NYSE, while PSNL trades at $12.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas PSNL's P/E ratio is -12.41. In terms of profitability, A's ROE is +0.21%, compared to PSNL's ROE of -0.44%. Regarding short-term risk, A is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for A.Check PSNL's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
A vs CSTL Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, CSTL has a market cap of 849.2M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while CSTL trades at $28.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas CSTL's P/E ratio is -63.64. In terms of profitability, A's ROE is +0.21%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, A is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for A.Check CSTL's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
A vs GRALV Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas GRALV's P/E ratio is N/A. In terms of profitability, A's ROE is +0.21%, compared to GRALV's ROE of N/A. Regarding short-term risk, A is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for A.Check GRALV's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
A vs FLGT Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, FLGT has a market cap of 470M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while FLGT trades at $16.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas FLGT's P/E ratio is 1655.00. In terms of profitability, A's ROE is +0.21%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, A is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for A.Check FLGT's competition here
Global Cord Blood Corporation (NYSE: CO)
A vs CO Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas CO's P/E ratio is 5.06. In terms of profitability, A's ROE is +0.21%, compared to CO's ROE of +0.11%. Regarding short-term risk, A is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for A.Check CO's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
A vs NEO Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, NEO has a market cap of 392.9M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while NEO trades at $15.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas NEO's P/E ratio is 117.62. In terms of profitability, A's ROE is +0.21%, compared to NEO's ROE of -0.06%. Regarding short-term risk, A is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for A.Check NEO's competition here
Prenetics Global Limited (NASDAQ: PRENW)
A vs PRENW Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, PRENW has a market cap of 360.8M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas PRENW's P/E ratio is N/A. In terms of profitability, A's ROE is +0.21%, compared to PRENW's ROE of -0.47%. Regarding short-term risk, A is more volatile compared to PRENW. This indicates higher risk in terms of short-term price fluctuations for A.Check PRENW's competition here
Prenetics Global Limited (NASDAQ: PRE)
A vs PRE Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, PRE has a market cap of 316.9M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while PRE trades at $18.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas PRE's P/E ratio is -9.05. In terms of profitability, A's ROE is +0.21%, compared to PRE's ROE of -0.47%. Regarding short-term risk, A is less volatile compared to PRE. This indicates lower risk in terms of short-term price fluctuations for A.Check PRE's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
A vs FLDM Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas FLDM's P/E ratio is -4.74. In terms of profitability, A's ROE is +0.21%, compared to FLDM's ROE of +0.17%. Regarding short-term risk, A is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for A.Check FLDM's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
A vs MYGN Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, MYGN has a market cap of 270.1M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while MYGN trades at $2.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas MYGN's P/E ratio is -22.00. In terms of profitability, A's ROE is +0.21%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, A is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for A.Check MYGN's competition here
Trinity Biotech plc (NASDAQ: TRIB)
A vs TRIB Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, TRIB has a market cap of 234.9M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while TRIB trades at $11.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas TRIB's P/E ratio is -3.01. In terms of profitability, A's ROE is +0.21%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, A is less volatile compared to TRIB. This indicates lower risk in terms of short-term price fluctuations for A.Check TRIB's competition here
Biodesix, Inc. (NASDAQ: BDSX)
A vs BDSX Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, BDSX has a market cap of 172.6M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while BDSX trades at $21.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas BDSX's P/E ratio is -5.22. In terms of profitability, A's ROE is +0.21%, compared to BDSX's ROE of -21.01%. Regarding short-term risk, A is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for A.Check BDSX's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
A vs IMDX Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, IMDX has a market cap of 150.1M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while IMDX trades at $4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas IMDX's P/E ratio is -3.91. In terms of profitability, A's ROE is +0.21%, compared to IMDX's ROE of +3.81%. Regarding short-term risk, A is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for A.Check IMDX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
A vs GTH Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas GTH's P/E ratio is -1.11. In terms of profitability, A's ROE is +0.21%, compared to GTH's ROE of -1.01%. Regarding short-term risk, A is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for A.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
A vs GENE Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas GENE's P/E ratio is -38.25. In terms of profitability, A's ROE is +0.21%, compared to GENE's ROE of -1.85%. Regarding short-term risk, A is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for A.Check GENE's competition here
Exagen Inc. (NASDAQ: XGN)
A vs XGN Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, XGN has a market cap of 109.4M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while XGN trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas XGN's P/E ratio is -6.12. In terms of profitability, A's ROE is +0.21%, compared to XGN's ROE of -1.14%. Regarding short-term risk, A is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for A.Check XGN's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
A vs SERA Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, SERA has a market cap of 79.8M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while SERA trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas SERA's P/E ratio is -3.22. In terms of profitability, A's ROE is +0.21%, compared to SERA's ROE of -0.41%. Regarding short-term risk, A is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for A.Check SERA's competition here
Atlantic International Corp. (NASDAQ: ATLN)
A vs ATLN Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas ATLN's P/E ratio is -0.68. In terms of profitability, A's ROE is +0.21%, compared to ATLN's ROE of +14.94%. Regarding short-term risk, A is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for A.Check ATLN's competition here
DarioHealth Corp. (NASDAQ: DRIO)
A vs DRIO Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, DRIO has a market cap of 53.2M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while DRIO trades at $7.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas DRIO's P/E ratio is -1.24. In terms of profitability, A's ROE is +0.21%, compared to DRIO's ROE of +0.93%. Regarding short-term risk, A is less volatile compared to DRIO. This indicates lower risk in terms of short-term price fluctuations for A.Check DRIO's competition here
Precipio, Inc. (NASDAQ: PRPO)
A vs PRPO Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, PRPO has a market cap of 38.7M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while PRPO trades at $21.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas PRPO's P/E ratio is -83.27. In terms of profitability, A's ROE is +0.21%, compared to PRPO's ROE of -0.07%. Regarding short-term risk, A is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for A.Check PRPO's competition here
Akumin Inc. (NASDAQ: AKU)
A vs AKU Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas AKU's P/E ratio is -0.13. In terms of profitability, A's ROE is +0.21%, compared to AKU's ROE of -5.32%. Regarding short-term risk, A is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for A.Check AKU's competition here
MDxHealth S.A. (NASDAQ: MDXH)
A vs MDXH Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, MDXH has a market cap of 21.5M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while MDXH trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas MDXH's P/E ratio is -1.10. In terms of profitability, A's ROE is +0.21%, compared to MDXH's ROE of +4.03%. Regarding short-term risk, A is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for A.Check MDXH's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
A vs CEMI Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas CEMI's P/E ratio is -0.63. In terms of profitability, A's ROE is +0.21%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, A is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for A.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
A vs ENZ Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas ENZ's P/E ratio is -2.24. In terms of profitability, A's ROE is +0.21%, compared to ENZ's ROE of -0.10%. Regarding short-term risk, A is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for A.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
A vs PMD Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas PMD's P/E ratio is -5.24. In terms of profitability, A's ROE is +0.21%, compared to PMD's ROE of -0.32%. Regarding short-term risk, A is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for A.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
A vs ME Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas ME's P/E ratio is -0.03. In terms of profitability, A's ROE is +0.21%, compared to ME's ROE of -42.03%. Regarding short-term risk, A is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for A.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
A vs MYNZ Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, A's ROE is +0.21%, compared to MYNZ's ROE of -10.25%. Regarding short-term risk, A is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for A.Check MYNZ's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
A vs QUCY Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, QUCY has a market cap of 14.3M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while QUCY trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas QUCY's P/E ratio is -0.05. In terms of profitability, A's ROE is +0.21%, compared to QUCY's ROE of -3.26%. Regarding short-term risk, A is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for A.Check QUCY's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
A vs BNGO Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, BNGO has a market cap of 12.3M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while BNGO trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas BNGO's P/E ratio is -0.24. In terms of profitability, A's ROE is +0.21%, compared to BNGO's ROE of -0.71%. Regarding short-term risk, A is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for A.Check BNGO's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
A vs CHEK Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas CHEK's P/E ratio is -0.43. In terms of profitability, A's ROE is +0.21%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, A is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for A.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
A vs CNTG Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas CNTG's P/E ratio is -0.23. In terms of profitability, A's ROE is +0.21%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, A is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for A.Check CNTG's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
A vs BNR Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, BNR has a market cap of 9.3M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while BNR trades at $8.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas BNR's P/E ratio is -10.73. In terms of profitability, A's ROE is +0.21%, compared to BNR's ROE of -0.11%. Regarding short-term risk, A is more volatile compared to BNR. This indicates higher risk in terms of short-term price fluctuations for A.Check BNR's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
A vs ADVB Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, ADVB has a market cap of 8.7M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while ADVB trades at $8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas ADVB's P/E ratio is -72.73. In terms of profitability, A's ROE is +0.21%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, A is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for A.Check ADVB's competition here
Check-Cap Ltd. Ordinary Share (NASDAQ: MBAI)
A vs MBAI Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, MBAI has a market cap of 7.4M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while MBAI trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas MBAI's P/E ratio is 1.58. In terms of profitability, A's ROE is +0.21%, compared to MBAI's ROE of +4.17%. Regarding short-term risk, A is less volatile compared to MBAI. This indicates lower risk in terms of short-term price fluctuations for A.Check MBAI's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
A vs APDN Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas APDN's P/E ratio is -0.10. In terms of profitability, A's ROE is +0.21%, compared to APDN's ROE of -6.53%. Regarding short-term risk, A is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for A.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
A vs NVTA Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas NVTA's P/E ratio is -0.00. In terms of profitability, A's ROE is +0.21%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, A is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for A.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
A vs LMDX Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas LMDX's P/E ratio is -0.01. In terms of profitability, A's ROE is +0.21%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, A is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for A.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
A vs LMDXW Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, A's ROE is +0.21%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, A is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for A.Check LMDXW's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
A vs NDRA Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, NDRA has a market cap of 3.6M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while NDRA trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas NDRA's P/E ratio is -0.61. In terms of profitability, A's ROE is +0.21%, compared to NDRA's ROE of -5.13%. Regarding short-term risk, A is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for A.Check NDRA's competition here
DermTech, Inc. (NASDAQ: DMTK)
A vs DMTK Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas DMTK's P/E ratio is -0.04. In terms of profitability, A's ROE is +0.21%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, A is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for A.Check DMTK's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
A vs BIAF Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, BIAF has a market cap of 2.8M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while BIAF trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas BIAF's P/E ratio is -0.07. In terms of profitability, A's ROE is +0.21%, compared to BIAF's ROE of -3.59%. Regarding short-term risk, A is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for A.Check BIAF's competition here
Inotiv, Inc. (NASDAQ: NOTV)
A vs NOTV Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas NOTV's P/E ratio is -0.03. In terms of profitability, A's ROE is +0.21%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, A is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for A.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
A vs SQL Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas SQL's P/E ratio is -0.40. In terms of profitability, A's ROE is +0.21%, compared to SQL's ROE of +38.02%. Regarding short-term risk, A is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for A.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
A vs AWH Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas AWH's P/E ratio is -0.09. In terms of profitability, A's ROE is +0.21%, compared to AWH's ROE of +2.03%. Regarding short-term risk, A is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for A.Check AWH's competition here
Intelligent Bio Solutions Inc. (NASDAQ: INBS)
A vs INBS Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, INBS has a market cap of 1.2M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while INBS trades at $1.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas INBS's P/E ratio is -0.21. In terms of profitability, A's ROE is +0.21%, compared to INBS's ROE of -1.74%. Regarding short-term risk, A is less volatile compared to INBS. This indicates lower risk in terms of short-term price fluctuations for A.Check INBS's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
A vs HTGM Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, A is priced at $138.37 on the NYSE, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas HTGM's P/E ratio is -0.03. In terms of profitability, A's ROE is +0.21%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, A is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for A.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
A vs BIOC Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, A is priced at $138.37 on the NYSE, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas BIOC's P/E ratio is -0.01. In terms of profitability, A's ROE is +0.21%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, A is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for A.Check BIOC's competition here
iSpecimen Inc. (NASDAQ: ISPC)
A vs ISPC Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, ISPC has a market cap of 262.4K. Regarding current trading prices, A is priced at $138.37 on the NYSE, while ISPC trades at $1.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas ISPC's P/E ratio is -0.06. In terms of profitability, A's ROE is +0.21%, compared to ISPC's ROE of -5.85%. Regarding short-term risk, A is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for A.Check ISPC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
A vs SQLLW Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, A is priced at $138.37 on the NYSE, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, A's ROE is +0.21%, compared to SQLLW's ROE of +38.02%. Regarding short-term risk, A is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for A.Check SQLLW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
A vs CHEKZ Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, A is priced at $138.37 on the NYSE, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, A's ROE is +0.21%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, A is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for A.Check CHEKZ's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
A vs MEUSW Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, A is priced at $138.37 on the NYSE, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas MEUSW's P/E ratio is N/A. In terms of profitability, A's ROE is +0.21%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, A is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for A.Check MEUSW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
A vs PRXL Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, A is priced at $138.37 on the NYSE, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas PRXL's P/E ratio is 42.97. In terms of profitability, A's ROE is +0.21%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, A is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for A.Check PRXL's competition here
Danaher Corporation (NYSE: DHR-PA)
A vs DHR-PA Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, A is priced at $138.37 on the NYSE, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, A's ROE is +0.21%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, A is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for A.Check DHR-PA's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
A vs OCDX Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, A is priced at $138.37 on the NYSE, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas OCDX's P/E ratio is -42.28. In terms of profitability, A's ROE is +0.21%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, A is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for A.Check OCDX's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
A vs NDRAW Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, A is priced at $138.37 on the NYSE, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas NDRAW's P/E ratio is N/A. In terms of profitability, A's ROE is +0.21%, compared to NDRAW's ROE of -5.13%. Regarding short-term risk, A is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for A.Check NDRAW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
A vs BNGOW Comparison August 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 39.1B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, A is priced at $138.37 on the NYSE, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 23.82, whereas BNGOW's P/E ratio is N/A. In terms of profitability, A's ROE is +0.21%, compared to BNGOW's ROE of -0.71%. Regarding short-term risk, A is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for A.Check BNGOW's competition here